| Literature DB >> 30571262 |
Ashish R Panchal, Katherine M Berg, Peter J Kudenchuk, Marina Del Rios, Karen G Hirsch, Mark S Link, Michael C Kurz, Paul S Chan, José G Cabañas, Peter T Morley, Mary Fran Hazinski, Michael W Donnino.
Abstract
Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.Entities:
Keywords: AHA Scientific Statements; advanced cardiac life support, adult; anti-arrhythmia agents; cardiopulmonary resuscitation; heart arrest; tachycardia, ventricular; ventricular fibrillation
Mesh:
Substances:
Year: 2018 PMID: 30571262 PMCID: PMC7324904 DOI: 10.1161/CIR.0000000000000613
Source DB: PubMed Journal: Circulation ISSN: 0009-7322 Impact factor: 29.690